Cargando…
Equibalancing immune‐related adverse events and anticancer activity of immune checkpoint inhibitors
Autor principal: | Seeruttun, Sharvesh Raj |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775024/ https://www.ncbi.nlm.nih.gov/pubmed/31456312 http://dx.doi.org/10.1111/1759-7714.13180 |
Ejemplares similares
-
Re-engineering anti-CTLA-4 antibodies for enhancing cancer immunotherapy efficacy and safety
por: Seeruttun, Sharvesh Raj
Publicado: (2019) -
Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors
por: Wang, Zheng-Hang, et al.
Publicado: (2018) -
Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
por: Herrmann, Sandra M., et al.
Publicado: (2020) -
Cardiac Adverse Events Related to Immune Checkpoint Inhibitors
por: Gujral, Dorothy M., et al.
Publicado: (2020) -
Rheumatic immune‐related adverse events induced by immune checkpoint inhibitors
por: Zhong, Hui, et al.
Publicado: (2020)